Integra LifeSciences Holdings Corporation (NASDAQ:IART – Get Free Report) has been given a consensus recommendation of “Reduce” by the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation and three have given a hold recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $12.75.
A number of analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday. Citigroup increased their price target on shares of Integra LifeSciences from $9.00 to $11.00 and gave the company a “sell” rating in a report on Wednesday, May 6th. Argus restated a “hold” rating on shares of Integra LifeSciences in a research report on Wednesday, April 15th. Truist Financial reduced their price objective on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a report on Wednesday, April 15th. Finally, Wall Street Zen raised Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th.
Read Our Latest Stock Analysis on Integra LifeSciences
Integra LifeSciences Stock Down 2.8%
Integra LifeSciences (NASDAQ:IART – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The business had revenue of $391.92 million during the quarter, compared to the consensus estimate of $381.81 million. During the same quarter last year, the firm posted $0.41 EPS. The company’s quarterly revenue was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, research analysts anticipate that Integra LifeSciences will post 2.44 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in IART. Global Retirement Partners LLC acquired a new stake in shares of Integra LifeSciences during the fourth quarter worth $25,000. Osaic Holdings Inc. grew its stake in shares of Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after acquiring an additional 1,104 shares in the last quarter. GAMMA Investing LLC increased its position in Integra LifeSciences by 145.9% during the fourth quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock worth $78,000 after acquiring an additional 3,742 shares during the period. Tower Research Capital LLC TRC increased its position in Integra LifeSciences by 595.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after acquiring an additional 6,814 shares during the period. Finally, Virtu Financial LLC acquired a new stake in Integra LifeSciences in the 4th quarter worth about $124,000. 84.78% of the stock is owned by institutional investors and hedge funds.
About Integra LifeSciences
Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.
Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.
Further Reading
- Five stocks we like better than Integra LifeSciences
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
- MarketBeat Week in Review – 05/11 – 05/15
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
